Kathleen Moore
MD, MS
Deputy Director and Director of Phase 1
Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center

Kathleen Moore is a Professor in the Section of Gynecologic Oncology, Deputy Director and Director of the Phase I Program for the Buffett Cancer Center at the University of Nebraska Medical Center. She attended medical school at the University of Washington School of Medicine and completed her residency in obstetrics and gynecology at the University Health Center of Pittsburgh. Dr Moore completed a fellowship in gynecologic oncology at the University of Oklahoma Health Sciences Center while simultaneously earning a master's degree in epidemiology. She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care. She has published over 400 peer-reviewed publications and has a clinical research interest in drug development and phase I-3 clinical trials.

Sessions

Register
General Session

Front-Line Maintenance Therapy for Ovarian Cancer: It is a PARPi and Bevacizumab World – Don’t Fix What Is Not Broken vs We Can Do Better Than HRD – Opportunities for New Biomarkers and Agents to Improve Outcomes

Saturday, March 14, 2026
4:25 PM - 5:10 PM
General Session

Front-Line Metastatic Endometrial Cancer: Immunotherapy for All vs Molecular Profiling to Individualize Therapy – Immunotherapy Should Not Be an Empiric Selection

Sunday, March 15, 2026
2:10 PM - 2:55 PM
General Session

Treatment of Platinum-Sensitive and Resistant Recurrent Ovarian Cancer: Optimizing Outcomes with Currently Available Therapies – The Regulatory Standard Is the Treatment Standard vs Rethinking Recurrent Ovarian Cancer – ADCs, New Taxane Combinations,

Sunday, March 15, 2026
2:55 PM - 3:40 PM
General Session

Front-Line Metastatic Endometrial Cancer: Immunotherapy for All vs Molecular Profiling to Individualize Therapy – Immunotherapy Should Not Be an Empiric Selection

Sunday, September 27, 2026
1:30 PM - 2:15 PM
General Session

Front-Line Maintenance Therapy for Ovarian Cancer: It is a PARPi and Bevacizumab World – Don’t Fix What Is Not Broken vs We Can Do Better Than HRD – Opportunities for New Biomarkers and Agents to Improve Outcomes

Sunday, September 27, 2026
3:30 PM - 4:15 PM
Back to top